New hope for tough esophageal cancer: targeted drug combo shows promise
NCT ID NCT07403136
First seen Feb 21, 2026 · Last updated May 20, 2026 · Updated 14 times
Summary
This study tests a new drug, vebrekotuzumab, for people with advanced esophageal cancer that stopped responding to initial treatment. The drug is designed to deliver a strong cancer-killing agent directly to tumor cells, potentially slowing or shrinking the cancer. About 104 participants will receive the drug alone or with an immunotherapy, and researchers will measure how many patients see their tumors shrink or stabilize.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.